

Jonas Oldgren

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/7166441/publications.pdf](https://exaly.com/author-pdf/7166441/publications.pdf)

Version: 2025-02-01

119

PR articles

38,287

PR citations

33822

46

PR h-index

13424

116

g-index

123

documents

42171

doc citations

38279

48

h-index

29428

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure. European Heart Journal - Cardiovascular Pharmacotherapy, 2024, 10, 91-92.	4.1	5
2	Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. Journal of the American Heart Association, 2024, 13, .	4.3	12
3	Patientsâ€™ experiences of clinical trial participation involving a product remotely assessing study drug adherence. Contemporary Clinical Trials Communications, 2024, 40, 101307.	1.2	0
4	Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry. European Heart Journal, 2024, 45, 2336-2340.	2.3	3
5	SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study. Diabetes Care, 2024, 47, 1630-1637.	6.5	4
6	Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation. Circulation, 2024, 150, 1090-1100.	25.2	9
7	Sex differences in prevalence and characteristics of imaging-detected atherosclerosis: a population-based study. European Heart Journal Cardiovascular Imaging, 2024, 25, 1663-1672.	1.4	14
8	Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. European Heart Journal, 2023, 44, 208-218.	2.3	47
9	Plasma angiotensin-converting enzyme 2 and its association with heart failure in patients with atrial fibrillation. Europace, 2023, 25, .	2.1	9
10	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 216-226.	4.1	29
11	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. Cardiovascular Research, 2022, 118, 295-304.	5.7	15
12	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovascular Research, 2022, 118, 2112-2123.	5.7	40
13	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	25.2	322
14	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute Cardiovascular Care and the Asia-Pacific Heart Rhythm Society. Europace, 2022, 24, 1844-1871.	2.1	51
15	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. American Heart Journal, 2022, 251, 13-24.	3.0	16
16	Serum Neurofilament Light Chain in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, .	4.3	22
17	Is the ESC blowing its own trumpet or should it have a deserved fanfare? The impact and power of registry data. European Heart Journal Quality of Care & Clinical Outcomes, 2022, , .	3.8	1
18	Early Versus Delayed Nonâ€“Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation, 2022, 146, 1056-1066.	25.2	146

#	ARTICLE	IF	PR CITATIONS
19	Systematic Coronary Risk Evaluation estimated risk and prevalent subclinical atherosclerosis in coronary and carotid arteries: A population-based cohort analysis from the Swedish Cardiopulmonary Bioimage Study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 250-259.	2.1	33
20	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f50-f60.	4.1	37
21	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	2.3	8,378
22	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021, 233, 92-101.	3.0	12
23	Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1505-1517.	4.7	54
24	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 768-780.	3.2	7
25	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	2.1	861
26	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL) Tj ETQq0 0 0 rgBT /Overlock 10 T Cardiology, 2021, 44, 1002-1010.	2.1	3
27	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2726-2737.	3.9	26
28	Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2021, 81, 353-360.	1.3	2
29	Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 53, 74-82.	2.0	2
30	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021, 23, 329-344.	2.1	59
31	Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 8, 363-371.	4.1	3
32	Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1311-1319.	2.1	4
33	Weight gain and blood pressure. <i>Journal of Hypertension</i> , 2020, 38, 387-394.	2.3	13
34	Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Tj ETQq0 0 0 rgBT /O	1.9	16
35	Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic. <i>Heart</i> , 2020, 106, 1812-1818.	4.3	48
36	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 4037-4046.	2.3	107

#	ARTICLE	IF	PR CITATIONS
37	Evaluation of the Age, Biomarkers, and Clinical Historyâ€“Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	6.8	8
38	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , 2020, 133, 1302-1312.	2.3	5
39	Serial measurement of interleukinâ€“6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and REâ€“LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295.	3.9	21
40	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. <i>Drugs</i> , 2020, 80, 995-1005.	11.8	13
41	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. <i>Europace</i> , 2020, 22, 870-877.	2.1	21
42	Post-resuscitation myocardial dysfunction in out-of-hospital cardiac arrest patients randomized to immediate coronary angiography versus standard of care. <i>IJC Heart and Vasculature</i> , 2020, 27, 100483.	0.8	8
43	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <i>PLoS ONE</i> , 2020, 15, e0226259.	2.4	1
44	Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, .	5.7	22
45	Risk of ischemic stroke and utility of CHA ₂ DS ₂ -VASc score in women and men with atrial fibrillation. <i>Clinical Cardiology</i> , 2019, 42, 1003-1009.	2.1	39
46	Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1553-1561.	3.2	12
47	Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease. <i>JRSM Cardiovascular Disease</i> , 2019, 8, .	1.2	2
48	Direct or subacute coronary angiography in out-of-hospital cardiac arrest (DISCO)â€“An initial pilot-study of a randomized clinical trial. <i>Resuscitation</i> , 2019, 139, 253-261.	2.8	73
49	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. <i>European Heart Journal</i> , 2019, 40, 1553-1562.	2.3	74
50	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. <i>American Heart Journal</i> , 2019, 212, 13-22.	3.0	13
51	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Postâ€“PCI in Patients With Atrial Fibrillation and Diabetes. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2346-2355.	3.2	16
52	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2331-2341.	3.2	9
53	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the REâ€“LY Trial. <i>Journal of the American Heart Association</i> , 2019, 8, .	4.3	22
54	Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patientsâ€“a description of the DAPACARD study. <i>Upsala Journal of Medical Sciences</i> , 2019, 124, 59-64.	0.8	17

#	ARTICLE	IF	PR CITATIONS
55	Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. <i>European Heart Journal</i> , 2018, 39, 2959-2971.	2.3	152
56	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2018, 39, 1726-1735a.	2.3	146
57	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, Tj ETQq1 1 0.784314 rrgBT /Overlock 10	2.5	111
58	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. <i>American Heart Journal</i> , 2018, 198, 169-177.	3.0	15
59	Design of DISCO—Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study. <i>American Heart Journal</i> , 2018, 197, 53-61.	3.0	25
60	Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 36-45.	4.1	14
61	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	2.1	104
62	Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG—Short- and long-term survival. <i>American Heart Journal</i> , 2018, 200, 90-95.	3.0	41
63	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	2.1	213
64	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	2.3	1,794
65	Effects of sauna bath on heart failure: A systematic review and meta-analysis. <i>Clinical Cardiology</i> , 2018, 41, 1491-1501.	2.1	22
66	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 255-267.	2.4	71
67	Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. <i>Revista Espanola De Cardiología</i> , 2017, 70, 50.e1-50.e84.	1.1	15
68	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	4.3	85
69	Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. <i>Current Heart Failure Reports</i> , 2017, 14, 59-70.	3.1	77
70	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	3.0	49
71	Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. <i>Clinical Chemistry</i> , 2017, 63, 152-164.	1.1	92
72	Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <i>Open Heart</i> , 2017, 4, e000682.	2.5	32

#	ARTICLE	IF	PR CITATIONS
73	Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events. <i>Circulation</i> , 2017, 136, 1183-1192.	25.2	148
74	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. <i>Europace</i> , 2017, 19, 1630-1636.	2.1	19
75	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 377, 1513-1524.	43.7	1,241
76	The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients. <i>Uppsala Journal of Medical Sciences</i> , 2017, 122, 224-233.	0.8	20
77	Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. <i>PLoS ONE</i> , 2017, 12, e0181000.	2.4	32
78	Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. <i>American Heart Journal</i> , 2016, 179, 59-68.	3.0	32
79	All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. <i>Heart</i> , 2016, 102, 926-933.	4.3	93
80	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet</i> , The, 2016, 387, 2302-2311.	52.8	447
81	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.	1.4	823
82	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <i>Lancet</i> , The, 2016, 388, 1161-1169.	52.8	271
83	Genetic Determinants of Warfarin Maintenance Dose and Time in Therapeutic Treatment Range: A RE-LY Genomics Substudy. <i>Pharmacogenomics</i> , 2016, 17, 1425-1439.	1.6	23
84	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	2.3	6,082
85	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016, 18, 1609-1678.	2.1	3,691
86	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	25.2	89
87	Design and Rationale of the <sc>REÅ€DUAL PCI</sc> Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etxilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016, 39, 555-564.	2.1	66
88	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016, 102, 57-62.	4.3	34
89	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016, 139, 77-81.	2.4	42
90	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1582-1590.	2.3	401

#	ARTICLE	IF	PR CITATIONS
91	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	2.1	19
92	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	2.1	134
93	Association Between the Use of Fondaparinux vs Low-Molecular-Weight Heparin and Clinical Outcomes in Patients With Nonâ€ST-Segment Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 707.	17.1	38
94	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	2.1	992
95	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 1151-1160.	3.0	124
96	Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 961-970.	25.2	376
97	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. <i>Circulation</i> , 2014, 129, 1568-1576.	25.2	350
98	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. <i>Heart</i> , 2014, 100, 1193-1200.	4.3	50
99	Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?. <i>Internal and Emergency Medicine</i> , 2013, 8, 673-680.	3.2	10
100	Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. <i>Circulation</i> , 2013, 127, 634-640.	25.2	462
101	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2013, 15, 625-651.	2.1	741
102	Biomarkers in atrial fibrillation: a clinical review. <i>European Heart Journal</i> , 2013, 34, 1475-1480.	2.3	276
103	New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2013, 34, 1670-1680.	2.3	180
104	Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. <i>European Heart Journal</i> , 2013, 34, 177-183.	2.3	57
105	Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. <i>Circulation</i> , 2012, 125, 669-676.	25.2	348
106	Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 125, 1605-1616.	25.2	384
107	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS ₂ Score: A Subgroup Analysis of the RE-LY Trial. <i>Annals of Internal Medicine</i> , 2011, 155, 660.	10.4	183
108	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372.	25.2	1,081

#	ARTICLE	IF	PR CITATIONS
109	Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. <i>European Heart Journal</i> , 2011, 32, 2781-2789.	2.3	496
110	Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA. <i>Heart</i> , 2010, 96, 1451-1457.	4.3	27
111	Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. <i>American Heart Journal</i> , 2009, 157, 805-810.e2.	3.0	306
112	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	43.7	10,494
113	Xa inhibition and coagulation activity—the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. <i>American Heart Journal</i> , 2008, 155, 493.e1-493.e8.	3.0	6
114	Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. <i>European Heart Journal</i> , 2008, 29, 315-323.	2.3	38
115	Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial. <i>European Heart Journal</i> , 2007, 28, 692-698.	2.3	28
116	Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. <i>European Heart Journal</i> , 2007, 28, 699-704.	2.3	57
117	An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. <i>American Heart Journal</i> , 2005, 149, 619-626.	3.0	61
118	Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2004, 91, 381-387.	4.2	13
119	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 0, , ehw058.	2.3	210